Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization.

Trial Profile

Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Apr 2018

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms EXCEL
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 02 Nov 2017 Results assessing impact of cerebrovascular disease in patients with left main coronary artery disease following revascularization presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
    • 02 Nov 2017 Results assessing effect of number of diseased coronary arteries on outcomes,presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
    • 02 Nov 2017 Results of propensity score matched analysis assessing impact of chronic obstructive pulmonary disease on outcomes presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top